Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $979.64 billion. The enterprise value is $1.02 trillion.
| Market Cap | 979.64B |
| Enterprise Value | 1.02T |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | May 15, 2026 |
Share Statistics
Eli Lilly has 891.74 million shares outstanding. The number of shares has decreased by -0.57% in one year.
| Current Share Class | 891.74M |
| Shares Outstanding | 891.74M |
| Shares Change (YoY) | -0.57% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 89.30% |
| Float | 889.33M |
Valuation Ratios
The trailing PE ratio is 39.02 and the forward PE ratio is 29.47. Eli Lilly's PEG ratio is 1.36.
| PE Ratio | 39.02 |
| Forward PE | 29.47 |
| PS Ratio | 13.56 |
| Forward PS | 11.25 |
| PB Ratio | 31.46 |
| P/TBV Ratio | 55.37 |
| P/FCF Ratio | 82.86 |
| P/OCF Ratio | 47.83 |
| PEG Ratio | 1.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.09, with an EV/FCF ratio of 86.04.
| EV / Earnings | 40.25 |
| EV / Sales | 14.08 |
| EV / EBITDA | 28.09 |
| EV / EBIT | 29.77 |
| EV / FCF | 86.04 |
Financial Position
The company has a current ratio of 1.50, with a Debt / Equity ratio of 1.39.
| Current Ratio | 1.50 |
| Quick Ratio | 0.72 |
| Debt / Equity | 1.39 |
| Debt / EBITDA | 1.19 |
| Debt / FCF | 3.67 |
| Interest Coverage | 388.32 |
Financial Efficiency
Return on equity (ROE) is 107.46% and return on invested capital (ROIC) is 41.92%.
| Return on Equity (ROE) | 107.46% |
| Return on Assets (ROA) | 20.74% |
| Return on Invested Capital (ROIC) | 41.92% |
| Return on Capital Employed (ROCE) | 42.75% |
| Weighted Average Cost of Capital (WACC) | 6.80% |
| Revenue Per Employee | $1.44M |
| Profits Per Employee | $505,540 |
| Employee Count | 50,000 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.04 |
Taxes
In the past 12 months, Eli Lilly has paid $5.85 billion in taxes.
| Income Tax | 5.85B |
| Effective Tax Rate | 18.79% |
Stock Price Statistics
The stock price has increased by +38.84% in the last 52 weeks. The beta is 0.52, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +38.84% |
| 50-Day Moving Average | 1,011.09 |
| 200-Day Moving Average | 966.09 |
| Relative Strength Index (RSI) | 53.98 |
| Average Volume (20 Days) | 3,193,280 |
Short Selling Information
The latest short interest is 9.80 million, so 1.10% of the outstanding shares have been sold short.
| Short Interest | 9.80M |
| Short Previous Month | 7.86M |
| Short % of Shares Out | 1.10% |
| Short % of Float | 1.10% |
| Short Ratio (days to cover) | 2.75 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $72.25 billion and earned $25.28 billion in profits. Earnings per share was $28.15.
| Revenue | 72.25B |
| Gross Profit | 59.85B |
| Operating Income | 34.17B |
| Pretax Income | 31.13B |
| Net Income | 25.28B |
| EBITDA | 36.22B |
| EBIT | 34.17B |
| Earnings Per Share (EPS) | $28.15 |
Balance Sheet
The company has $5.28 billion in cash and $43.37 billion in debt, with a net cash position of -$37.64 billion or -$42.21 per share.
| Cash & Cash Equivalents | 5.28B |
| Total Debt | 43.37B |
| Net Cash | -37.64B |
| Net Cash Per Share | -$42.21 |
| Equity (Book Value) | 31.20B |
| Book Value Per Share | 34.92 |
| Working Capital | 18.20B |
Cash Flow
In the last 12 months, operating cash flow was $20.48 billion and capital expenditures -$8.66 billion, giving a free cash flow of $11.82 billion.
| Operating Cash Flow | 20.48B |
| Capital Expenditures | -8.66B |
| Depreciation & Amortization | 2.04B |
| Net Borrowing | 4.46B |
| Free Cash Flow | 11.82B |
| FCF Per Share | $13.26 |
Margins
Gross margin is 82.83%, with operating and profit margins of 47.30% and 34.99%.
| Gross Margin | 82.83% |
| Operating Margin | 47.30% |
| Pretax Margin | 43.08% |
| Profit Margin | 34.99% |
| EBITDA Margin | 50.13% |
| EBIT Margin | 47.30% |
| FCF Margin | 16.36% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 0.63%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 0.63% |
| Dividend Growth (YoY) | 15.36% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 22.95% |
| Buyback Yield | 0.57% |
| Shareholder Yield | 1.20% |
| Earnings Yield | 2.58% |
| FCF Yield | 1.21% |
Analyst Forecast
The average price target for Eli Lilly is $1,218.72, which is 10.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $1,218.72 |
| Price Target Difference | 10.67% |
| Analyst Consensus | Buy |
| Analyst Count | 31 |
| Revenue Growth Forecast (3Y) | 19.27% |
| EPS Growth Forecast (3Y) | 28.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 7.62 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.62 |
| Piotroski F-Score | 6 |